Tesamorelin
Tesamorelin • Also called Egrifta
Tesamorelin has an FDA-approved reference product, which gives it a materially clearer regulatory footing than most wellness-market peptides.
Current status
Legal
Growth-hormone-related interest, with current federal compounding constraints still in play.
FDA category
FDA Approved
Can pharmacies compound this?
Yes
Reclassification expected?
Unclear
Its main relevance here is as a contrast case: it has an approved drug pathway instead of relying on speculative policy change.
Primary Use
Growth-hormone-related interest
Also searched as
Egrifta
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Nov 10, 2010
Ingredient remained available through approved or established compounding pathways.
Get notified...
Get notified when Tesamorelin status changes
State-specific notes
Tennessee
More defensible than non-approved secretagogues when clinics want a peptide with a clearer federal basis.